Read the original:
Apollomics Receives Nasdaq Notification Regarding Minimum Bid Price Deficiency
Allogene Therapeutics to Host Conference Call Previewing its 2024 Platform Vision and Present at the 42nd Annual J.P. Morgan Healthcare Conference
ORYZON to Host KOL Event on Phase IIb PORTICO Topline Study Results of Vafidemstat in Borderline Personality Disorder on January 25, 2024
Santhera’s AGAMREE® (Vamorolone) Approved in the European Union for the Treatment of Duchenne Muscular Dystrophy
FDA Approves Arcutis’ ZORYVE® (roflumilast) Topical Foam, 0.3% for the Treatment of Seborrheic Dermatitis in Individuals Aged 9 Years and Older
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
Read the rest here:
MDxHealth Announces Completion of Transition to Single Listing on Nasdaq
Ultimovacs Announces Completion of Exploratory Phase I TENDU Study of TET Vaccine Technology Platform Meeting the Primary Endpoint
Annovis Bio Appoints Andrew Walsh as Vice President Finance
Nicox Announces First Patient Screened in the Whistler Phase 3b Trial of NCX 470 in Glaucoma
Mithra Receives Positive DSMB Opinion on DONESTA® European Phase 3 Trial
Akari Therapeutics Appoints Experienced Life Sciences Entrepreneur Samir R. Patel, M.D. to Board of Directors
Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)
Weight Loss Treatment: SciSparc’s Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Spectral Medical Announces CFO Departure
Originally posted here:
Spectral Medical Announces CFO Departure
Allogene Therapeutics Announces Participation in December Investor Conference
Read the original post:
Allogene Therapeutics Announces Participation in December Investor Conference
Weight loss MEAI: Clearmind Medicine’s Novel Obesity Drug Showed Positive Results in a Pre-Clinical Trial
Scilex Holding Company Generates Monthly Revenue In November 2023 And Provides Certain Preliminary Unaudited Financial Results For Gross And Net Sales…
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting
Read the original here:
Avenue Therapeutics to Present at American Epilepsy Society 2023 Annual Meeting